Health Care [ 12/12 ] | Biotechnology [ 62/74 ]
NASDAQ | Common Stock
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery.
The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.
Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer.
The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited.
Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 8, 24 | -0.40 Decreased by -5.26% | -0.40 |
| May 9, 24 | -0.39 Decreased by -14.71% | -0.42 Increased by +7.14% |
| Feb 27, 24 | -0.42 Decreased by -35.48% | -0.45 Increased by +6.67% |
| Nov 9, 23 | -0.43 Decreased by -22.86% | -0.38 Decreased by -13.16% |
| Aug 8, 23 | -0.38 Increased by 0.00% | -0.37 Decreased by -2.70% |
| May 8, 23 | -0.34 Decreased by -3.03% | -0.35 Increased by +2.86% |
| Feb 27, 23 | -0.31 Increased by +18.42% | -0.29 Decreased by -6.90% |
| Nov 8, 22 | -0.35 Decreased by -25.00% | -0.38 Increased by +7.89% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 26.08 M Increased by +158.19% | -95.67 M Decreased by -2.86% | Decreased by -366.82% Increased by +60.16% |
| Jun 30, 24 | 14.42 M Increased by +30.87% | -97.54 M Decreased by -27.13% | Decreased by -676.56% Increased by +2.86% |
| Mar 31, 24 | 13.79 M Increased by +13.68% | -91.37 M Decreased by -50.31% | Decreased by -662.41% Decreased by -32.22% |
| Dec 31, 23 | 10.89 M Decreased by -20.36% | -93.00 M Decreased by -61.79% | Decreased by -853.88% Decreased by -103.16% |
| Sep 30, 23 | 10.10 M Decreased by -22.61% | -93.02 M Decreased by -59.50% | Decreased by -920.78% Decreased by -106.10% |
| Jun 30, 23 | 11.02 M Increased by +43.94% | -76.73 M Decreased by -17.06% | Decreased by -696.50% Increased by +18.68% |
| Mar 31, 23 | 12.13 M Increased by +128.99% | -60.79 M Decreased by -8.60% | Decreased by -500.98% Increased by +52.58% |
| Dec 31, 22 | 13.68 M Increased by +447.04% | -57.48 M Increased by +11.48% | Decreased by -420.29% Increased by +83.82% |